The Filing Desk

Amrize

AMRZ · NYSE · Materials · Financials, fiscal 2023 to 2025

AMRZ · Last close · November 19, 2026
$40.01
Value Amrize yourself

Amrize's revenue rose 0.9% to $11.8 billion in fiscal 2025. Its operating margin was 16.1%, down from 18.8% a year earlier. Free cash flow was $1.4 billion, down 13.4%.

Amrize Ltd Latest fiscal year ended December 31, 2025 10-K filed February 18, 2026 · 0002035989-26-000017 Updated
Revenue
$11.8B
0.9%
Operating margin
16.1%
2.6 pts
Net income
$1.2B
7.0%
Free cash flow
$1.4B
13.4%
Return on equity
10.2%
 
Market cap
$21.8B
Nov 19 close
P/E
18.7x
On $2.14 EPS, FY25

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

What Amrize does

Amrize sells building materials and roofing and wall products in the United States and Canada. Its products include cement, aggregates (crushed stone, sand and gravel), ready-mix concrete, asphalt, roofing systems, insulation and coatings. It sells to home builders, commercial builders, architects, distributors, contractors and government authorities, for new construction and for repairs and refurbishment.

The company reports two segments. Building Materials sells cement, aggregates, ready-mix concrete and asphalt. Building Envelope sells roofing and wall systems under brands such as Duro-Last, Elevate and Malarkey. In Building Envelope, most revenue comes through a few large distributors. Amrize says it competes in a highly competitive industry.

Amrize says its 19,000 employees work across 1,000 sites in the United States, Canada, Colombia, Switzerland and Jamaica, serving 23,000 customers. It became a separate public company in June 2025, when Holcim distributed its shares to Holcim's shareholders.

Its biggest risks, as it describes them

  • Swings in construction demand, since it and its customers work in cyclical industries and regional markets.
  • Higher costs or shortages of raw materials, energy and fuel.
  • Failing to compete effectively in a highly competitive industry.
  • Trouble integrating acquisitions or joint ventures, or not getting the benefits it expects.
  • Losing, or facing price pressure from, key customers or distributors.
From Amrize's annual report on Form 10-K, filed February 18, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2023 to 2025, earnings per share grew 11.2% a year and net income 11.3% a year, with the share count about the same.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY23FY24FY25
Cash and short-term investments1,1071,5851,922
Debt incl. finance leases———
Net debt (negative means net cash)———
Net debt to EBITDA———
Debt to equity———
Interest coverage3.4x4.0x4.1x
Current ratio—1.9x1.6x
Quick ratio—1.3x1.1x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Amrize's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 12 insiders bought $9.9 million of Amrize shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 2, 2026Jan Philipp JenischChairman & CEO, DirectorBought30,000$42.47$1.3 millionForm 4
Aug 27, 2026Dwight Audley Konrad GibsonDirectorBought5$44.58$244Form 4
Aug 26, 2026Jacques Wolf SancheDirectorBought4,150$45.02$186,833Form 4
Aug 25, 2026Denise R SingletonChief Legal Officer & Corp SecBought3,500$44.12$154,420Form 4
Aug 25, 2026Nollaig ForrestChief Mktg & Corp Affairs OffBought1,500$44.15$66,225Form 4
Aug 17, 2026Samuel Jonas PolettiChief Strategy & M&A OfficerBought2,510$46.92$117,769Form 4
Aug 12, 2026Baris OranChief Financial OfficerBought3,000$47.13$141,390Form 4
Aug 11, 2026Stephen S ClarkChief People OfficerBought5,260$47.31$248,851Form 4
Aug 11, 2026Mario GrossChief Supply Chain OfficerBought3,568$46.60$166,252Form 4
Aug 11, 2026Baris OranChief Financial OfficerBought3,000$47.38$142,140Form 4
Aug 11, 2026Jaime HillPresident, Building MaterialsBought1,500$47.12$70,680Form 4
Aug 11, 2026Roald BrouwerChief Technology OfficerBought1,500$46.36$69,540Form 4
The latest 12 of 28 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY24FY25
Piotroski F-score——
Rule of 4014.2%13.0%
Altman Z''1.982.41
Accruals ratio—−4.3%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY24FY25
Net income is positive—Pass
Cash from operations is positivePassPass
Return on assets rose——
Cash from operations exceeds net incomePassPass
Debt fell relative to assets——
Current ratio rose—Fail
Share count didn't risePassFail
Gross margin rosePassFail
Revenue rose relative to assets——
F-score——
Companies that report no gross profit are scored on the other eight.

Compare

Put Amrize side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
AmrizeFY250.9%16.1%12.0%———
Vulcan MaterialsFY257.1%20.4%14.3%9.8%1.8x8Compare
Martin Marietta MaterialsFY258.6%23.4%15.9%7.7%2.7x7Compare
CRHFY255.3%14.5%7.8%11.8%1.9x7Compare
Knife RiverFY258.5%9.1%−2.2%9.1%2.3x3Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

3 years of figures

Fiscal yearFY23FY24FY25
Income statement
Revenue11,67711,70411,815
Revenue growth—0.2%0.9%
Gross profit2,7693,0703,034
Research and development———
Operating income1,8882,1951,906
Net income9561,2741,185
Diluted EPS (US$)1.732.302.14
Diluted shares (millions)553553554
Cash flow
Cash from operations2,0362,2822,208
Capital expenditure630642788
Free cash flow1,4061,6401,420
Dividends paid000
Share buybacks000
Acquisitions1,60724986
Stock-based compensation5614
Balance sheet at fiscal year end
Cash and short-term investments1,1071,5851,922
Debt incl. finance leases———
Total assets—23,80524,249
Total liabilities—13,89110,995
Shareholders' equity9,2039,91513,258
Margins and ratios
Gross margin23.7%26.2%25.7%
Operating margin16.2%18.8%16.1%
Net margin8.2%10.9%10.0%
Free cash flow margin12.0%14.0%12.0%
Rule of 40 (growth + FCF margin)—14.2%13.0%
Return on capital———
Return on equity——10.2%
Return on assets——4.9%
Net debt to EBITDA———
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Amrize's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Amrize.